Regeneron Pharmaceuticals Stock Forecast, Price & News

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 4 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Regeneron Pharmaceuticals stock.
View analyst ratings for Regeneron Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Regeneron Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Regeneron Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released its quarterly earnings results on Thursday, August, 5th. The biopharmaceutical company reported $25.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.81 by $16.99. The biopharmaceutical company earned $5.14 billion during the quarter, compared to analysts' expectations of $3.90 billion. Regeneron Pharmaceuticals had a net margin of 50.11% and a trailing twelve-month return on equity of 50.43%.
View Regeneron Pharmaceuticals' earnings history.

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, REGN stock has increased by 40.6% and is now trading at $653.18.
View which stocks have been most impacted by COVID-19.

Regeneron Pharmaceuticals announced that its Board of Directors has approved a share buyback plan on Tuesday, November 5th 2019, which permits the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 2.9% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board believes its shares are undervalued.

17 brokerages have issued 12 month target prices for Regeneron Pharmaceuticals' stock. Their forecasts range from $565.00 to $831.00. On average, they anticipate Regeneron Pharmaceuticals' share price to reach $698.38 in the next year. This suggests a possible upside of 6.9% from the stock's current price.
View analysts' price targets for Regeneron Pharmaceuticals or view top-rated stocks among Wall Street analysts.

423 employees have rated Regeneron Pharmaceuticals CEO Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among Regeneron Pharmaceuticals' employees.

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Novavax (NVAX), Incyte (INCY), Repligen (RGEN), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of REGN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), The Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and salesforce.com (CRM).

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (10.24%), BlackRock Inc. (8.48%), Vanguard Group Inc. (7.48%), State Street Corp (4.22%), Geode Capital Management LLC (1.60%) and Northern Trust Corp (1.09%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van and Robert E Landry.
View institutional ownership trends for Regeneron Pharmaceuticals.

REGN stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., BlackRock Inc., ARK Investment Management LLC, Susquehanna International Group LLP, Swiss National Bank, Nuveen Asset Management LLC, Woodline Partners LP, and AQR Capital Management LLC. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Arthur F Ryan, Bonnie L Bassler, George L Sing, George Yancopoulos, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, P Roy Vagelos, Plew Daniel P Van, and Robert E Landry.
View insider buying and selling activity for Regeneron Pharmaceuticals or view top insider-selling stocks.

REGN stock was bought by a variety of institutional investors in the last quarter, including Putnam Investments LLC, Amundi, Point72 Asset Management L.P., Bank of Nova Scotia, Canada Pension Plan Investment Board, Geode Capital Management LLC, Nikko Asset Management Americas Inc., and Mn Services Vermogensbeheer B.V..
View insider buying and selling activity for Regeneron Pharmaceuticals or or view top insider-buying stocks.

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of REGN stock can currently be purchased for approximately $653.18.

Regeneron Pharmaceuticals has a market capitalization of $69.86 billion and generates $8.50 billion in revenue each year. The biopharmaceutical company earns $3.51 billion in net income (profit) each year or $28.66 on an earnings per share basis.

Regeneron Pharmaceuticals employs 9,123 workers across the globe.

The following companies are subsidiares of Regeneron Pharmaceuticals: Loop Road Holdings LLC, OSMR Holdings, OSMR International, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.

Regeneron Pharmaceuticals was founded in 1988.

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

Regeneron Pharmaceuticals is headquartered at 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at (914) 847-7000 or via email at [email protected]